Triglycerides,LDL cholesterol and HOMA score predict the virological response in HIV/HCV co-infected patients treated with Pegylated interferon alpha 2a.

Slides:

Advertisements

Similar presentations

Optimal therapy in genotype 2 and 3 patients Antonio Craxì Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy

Advertisements

Body Composition and Metabolic Changes in Antiretroviral-Naïve HIV-Infected Patients Randomized to Didanosine and Stavudine (ddI+d4T) vs. Abacavir and.

Background  Hypertrigliceridaemia is common in patients with HIV, especially those taking protease inhibitors (PIs) or with lipodystrophy.  Although,

Liver Disease and Thalassaemia George Constantinou.

Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland.

Management of the HIV-infected patient with co-morbid diseases Christopher Behrens, MD Northwest AIDS Education & Training Center.

Hepatitis web study Hepatitis web study PEG alfa-2a + RBV versus PEG alfa-2a versus INF + RBV APRICOT STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

 During his annual physical in Dec 2007, Mr. A, a 42 y old pilot, presented with elevated liver enzymes and positive antibodies to HCV.  He had no symptoms.

Management of HCV in Co-Infected Patients Marie-Louise Vachon, MD, MSc Division of Infectious Diseases Centre Hospitalier Universitaire de Québec.

Mixed HCV Genotype Infection and Response to anti-HCV treatment in HIV/HCV Co-Infected Patients Lucy Porrino, Sabrina Bagaglio, Giulia Morsica, Giulia.

Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.

How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.

ABSTRACT BACKGROUND Background: Limited information is available on the impact of hepatitis C (HCV) co-infection on metabolic changes in HIV subjects starting.

Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.

Metabolic Syndrome, Diabetes, and Cognitive Impairment in the Era of Combination Antiretroviral Therapy Allen McCutchan 1, Jennifer Marquie-Beck 1, Scott.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin Paul Y Kwo, MD Professor of Medicine Medical Director,

Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.

LONG-TERM OUTCOME OF INTERFERON/RIBAVIRIN TREATMENT IN GERMAN REAL-LIFE SETTING: DURABLE SVR ASSOCIATED WITH LOW RATES OF LIVER-RELATED EVENTS S. Mauss.

Peginterferon Alfa-2a plus Ribavirin vs Peginterferon Alfa-2b plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV- Infected Patients J Berenguer.

Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.

Leptin Replacement Therapy Improves Insulin Resistance in Highly Active Antiretroviral Therapy (HAART) Induced Lipodystrophy and Metabolic Syndrome in.

Changes in Lipids in Randomised, Open-Label Comparative Trial of Abacavir or Tenofovir DF as Replacement for a Thymidine Analogue in Persons with Lipoatrophy.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

No prior therapy with PI

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

1 RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes Action Taken: TPV/r N=748 CPI/r N=737 Total Number of Grade 3 or 4 ALT,

Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.

Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.

HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.

Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,

Distinct hepatitis C virus kinetics in HIV- infected patients treated with ribavirin plus either pegylated interferon α-2a or α-2b Eugenia Vispo, Pablo.

02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:

SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.

FDA Hepatitis C Hearing Oct 19, 2006 Jules Levin Executive Director/Founder, NATAP National AIDS Treatment Advocacy Project.

Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.

 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.

Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.

C Sagnelli a, M Merli b, C Uberti-Foppa b, H Hasson b, G Bellini c, C Minichini d, S Salpietro b, E Messina b, N Coppola d, A Lazzarin b, E Sagnelli d,

Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

QUALI DIFFERENZE IN RAPPORTO AL SESSO NELLA COINFEZIONE HCV/HIV? I DATI ITALIANI DALLA COORTE ICONA Antonella Cingolani Clinica Malattie Infettive, UCSC,

METHODS INTRODUCTION I Webster, C Westcott, C Marincowitz, N Mashele, P De Boever, N Goswami, H Strijdom Division of Medical Physiology, Faculty of Medicine.

Maria Buti,1 Yoav Lurie,2 Natalia G. Zakharova,3 Natalia P. Blokhina,4 Andrzej Horban,5 Gerlinde Teuber,6 Christoph Sarrazin,6 Ligita Balciuniene,7 Saya.

KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.

Journal Conference Hepatology 2009;50: Background.

129 patients with chronic hepatitis C

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

ARV-trial.com Switch to ATV/r + 3TC ATLAS-M Study.

Phase 3 Treatment-Naïve and Treatment-Experienced

Berket Yemane, Melaku Umeta, Fikre Enquselassie, Wondwossen Amogne

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Sofosbuvir plus Peg-Interferon and Ribavirin in Treatment Experienced Patients with Hepatitis C Virus and HIV Co-Infection Mehri Nikbin, MD Infectious.

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.

A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova

DOES HIV/ HEPATITIS COINFECTION AFFECT PEOPLE ACCESSING CARE FOR HIV

World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.

Switch to DTG-containing regimen

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir Prof.dr.Abdel fattah hanno Dr. Doaa al wazzan.

Switch to RAL-containing regimen

Phase 3 Treatment-Naïve and Treatment-Experienced

Switch to DTG-containing regimen

Switch to ATV/r monotherapy

Phase 3 Treatment-Naïve and Treatment-Experienced

Presentation transcript:

Triglycerides,LDL cholesterol and HOMA score predict the virological response in HIV/HCV co-infected patients treated with Pegylated interferon alpha 2a and Ribavirn P.Nasta MD; F. Gatti MD, G. Cologni MD, A. Matti MD, M. Mendeni MD, L. Biasi MD, M. Puoti Prof and G. Carosi Prof. Paola Nasta MD Institute of Infectious and Tropical Diseases University of Brescia P.Le Spedali Civili, Brescia, ITALY Tel Institute of Infectious and Tropical Diseases, University of Brescia, Italy CONCLUSIONS Background Variable AAllRVR yespAOR(95% CI)pEVR yespOR(95% CI)pSVR yespAOR(95% CI)p Pts Number 9641/96(43)59/96(61,5)28/77(26,4) Age yrs M (+SD); Median (IQR) 42,5 (5,1) 42,5 (28-45,5) 42,2(6)0,641,8(6,1)0,140,8(+5,1)0,02 Female n (%) 16 (16,7)10(25)0,113(22,8)0,16(23,1)0,2 Body weight kg M (+SD); Median (IQR) 70,1 (12,8) 68 (61-67,5) 66(11,5)0,0268(11,1)0,0469,2(13,4)0,7 BMI Kg /m 2 M (+SD); Median (IQR) 23,6 (2,2) 23,3(21,2-25,5) 22,9(3,1)0,0523,2(3)0,0523,2(3)0,3 IDU n (%) 85 (88,5)36(90)0,451(89,5)0,324(92,3)0,2 Smokers n (%) 48 (51,1)24(61,5)0,0532(57,1)0,117(65,4)0,02 On methadone n (%) 6 (6,3)4(10)0,24(7)0,61(3,8)0,3 Alcohol users n (%) 28 (30,1,)13(34)0,218(32,7)0,26(23,1)0,3 Duration of HCV infection yrs M (+SD) Median (IQR) 10,1 (5,2) 9 (1-21) 13,9(5,9)0,110,6(5,6)0,116,6(5,8)0,5 Duration of HIV infection yrs M (+SD) Median (IQR) 15,8 (9,5) 16 (10-20) 13,9(6,0)0,0614,2(6)0,0613,6(5,8)0,02 CD4 nadir cell/mmc M (+SD) Median (IQR) 197 (141) 190 (96-269) 211(151)0,2214(154)0,1217(167)0,3 CD4 zenith M (+SD) Median (IQR) 688 (245) 680 ( ) 671(239)0,6669(228)0,4706(221)0,9 CDC class C n (%) 22(22,5)13(21)0,46(23,1)0,36(23,1)0,3 ART exposure yrs M (+SD); Median (IQR) 9,4(5,1) 10 (5-14) 8,1(5,1)0,018,4(5,1)0,0097,9(5)0,01 Currently On HAART n (%) PI based n (%) ABC based n (%) 85 (88) 73 (76) 49(16,7) 33(80,5) 39(66,1) 7(17,5) 0,03 0,08 0,5 49(83,1) 37(60,7) 9(15,3) 0,02 0,06 0,4 25(89,3) 37(61) 6(21,4) 0,5 0,06 0,3 HIV-RNA undetectable n (%) 85 (88%)33(80,5)0,0349(83,1)0,0225(89,3)0,5 Bl CD4 cell/mmc M (+SD) Median (IQR) CD4 > 500 cell /mmc n (%) 488 (200) 446 ( ) 39(40,6) 457(181) 13(31,7) 0,2 0,1 468(184) 22(37,3) 0,3 492(214) 8(28,6) 0,8 0,08 Genotype 1 -4 n (%) 51(53)12(29,3)<0,0010,05(0,007-0,3)0,00119(32,2)<0,0010,04(0,009-0,2)<0,00110 (35,7)0,0020,1(0,05-0,6)0,006 Advanced liver disease n (%) 53(57,6)20(50)0,126(48,1)0,029(34,6)0,008 Cirrhosis n (%) 28(29,2)7(17,1)0,0113(22,8)0,065(17,9)0,06 HCVRNA log IU/mL M(+SD) Median (IQR) HCVRNA < IU/mL n (%) 6,05(6.3) 5,7(4,9-7,0) 39(40,6) 5,71(5,79) 21(51,2) 0,003 0,07 5,8(+5,9) 28(47,5) 0,02 0,1 5,7(5,8) 17(60) 0,003 0,014,9(1,4-17,3)0,01 Tot Col mg/dL M (+SD); Median (IQR) Tot Chol > 200 mg/dl n(%) Chol LDL mg/dl M (+SD); Median (IQR) Chol HDL mg/dl M (+SD); Median (IQR) Chol HDL <40 n(%) 161 (41,5) 159 ( ) 14(14,6) 98(30,5) 93(74-117) 44,5 (13,5) 42 (32-52) 31(34,8) 164(40,7) 6(14,6) 106(27) 47,3(15,1) 10(26,3) 0,4 0,6 0,02 0,04 0,08 1,0(1-1,06)0,02 160(+41) 8(14) 99(29,4) 46,5(15) 37(69,8) 0,7 0,5 0,7 0,05 0,08 162(37) 3(10,7) 102(29) 43(11) 6(25) 0,6 0,5 0,2 0,8 0,2 TGD mg/dL M (+SD); Median (IQR) TGD > 150 mg/dL n(%) 145 (87,6) 125 (82-181) 34(35,4) 112(52) 6(14,6) 0,0004 <0,0010,16(0,03-0,8)0,003 0,001 0,0020,2(0,06-0,8)0,02 142(111) 8(28,6) 0,07 0,1 HOMA-IR < 3 n (%) 35 (46,1)25(62,5)<0,0017,3(1,4-38,5)0,0131(67,4)0,0035,4(1,4-20,4)0,0120(71,4)0,0056,5(1,7-24,1)0,004 Results Variables correlated with Rapid (RVR), Early (EVR) and Sustained (SVR) virologic response Aim and Methods HIV-HCV co-infected patients who started pegylated interferon alfa-2a (180 mcg/week) and Ribavirin mg/die(14 mg/kg(day) from January 2005 have been enrolled. At fasting insulin, glucose, total cholesterol, LDL (Low Density Lipoprotein), HDL (High Density Lipoprotein) and triglycerides (TGD) plasma level were measured in all patients on the first day of treatment with PegIFN/RBV and every three months HOMA-IR (HOMA: HOmeostasis Model of Assessment ) has been calculated as fasting insulin (mIU/L) × fasting glucose (mmol/L) ÷ 22.5; (normal range 0,7-2,25). HCV-RNA was measured by quantitative PCR assay (Versant 3.0) at baseline and HCV-RNA by qualitative PCR assay (COBAS 2.0) after 4 weeks of treatment and every three months. Patients with at least 3 months of anti HCV treatment entered in the analysis. Association between lipid and glucose parameters and RVR (Rapid Virologic Response), EVR (Early Virological Response) and SVR (Sustained Virological Response ) has been assessed Descriptive statistics are calculated for all the variables, data are expressed as number and percentage or mean (+SD) and median (IQR). All statistical analyses will be conducted at the alpha = 0.05 level and will be two-tailed. Baseline Variables in patients with or without RVR,EVR and SVR were compared using the Chi square test and Fisher’s exact test Variables possibly associated with RVR;EVR, SVR achievement were evaluated using the logistic regression model. Analyses were performed using Epi Info TM version (February 9,2005) HCV positive persons had an increase risk for type 2 diabetes mellitus particularly if cirrhotic (Knobler H et al. Mayo Clin Proc; 2000) and when older than 40 years (Mehta SH et al. Ann Intern Med; 2000) In HIV-HCV co-infected patients, insulin resistance is caused by both HCV infection and HAART therapy particularly when based on protease inhibitors (Braitstein P et al. AIDS; 2004) and thymidine analogues (Martin A et al. J Antimicrob and Chemoter; 2005) In HIV/HCV co-infected subjects, insulin resistance and LDL cholesterol are emerging as important host factors in the prediction of response in non diabetic patients treated with PEG-IFN plus ribavirin (Nasta P. et al, AIDS 2008; del Valle J et al. AIDS 2008) Metabolic parameters as insulin resistance (HOMA >3), Low Density Lipoproteins (LDL) and triglycerides are predictive factors for rapid, early and sustained virologic response in HIV/HCV co-infected patients treated with PegIFN/RBV Insulin resistance (HOMA-IR>3) represents the key metabolic factor in lipid and glucose metabolism impairment related with HCV and HIV/HAART. HOMA-IR >3 impairs RVR,EVR and SVR. LDL cholesterol level is usually lower in patients with viral hepatitis, in particular sustained by genotypes 2-3. Higher LDL level improves rapid virologic response in HV/HCV co-infected patients treated with PegIFN/RBV High level of triglycerides could be related with booth insulin resistance and antiretrovirals lypodistrophic effect. Hypertriglyceridemia represents a negative predictor in rapid and early virologic response in HIV/HCV co-infected subjects. Metabolic parameters have to be analysed and adjusted before to start treatment with PegIFN/RBV in HIV/HCV co- incfection.